- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Pharmacists Important in Chronic Disease Management, Study Finds
Published in the Journal of the American Pharmacists Association, the study found a significant improvement in the blood pressure of T2DM patients who were counseled by a pharmacist.
Results from a long-term study conducted at the University of Alberta found that an intergrated team of physicians and pharmacists can better help manage blood pressure in patients suffering from type 2 diabetes mellitus (T2DM).
This study, published in the Journal of the American Pharmacists Association, was part of a bigger study evaluating blood pressure control in T2DM patients. While the bigger study found that including pharmacists on the care team improved the health status of T2DM patients, the authors wanted to pinpoint the exact influence of pharmacists in managing hypertension in these patients.
The study showed that 42% of patients who were included in the intervention group, and received counselling by pharmacists, were twice as likely to show improvements in their blood pressure compared with patients in the non-intervention group.
Read more on EurekAlert!: http://bit.ly/1fgXJwq
Pulmonary Hypertension Subtypes Show Distinct PA Flow Hemodynamics
March 21st 2025Investigators used 4D flow cardiovascular magnetic resonance imaging to search for differences between pulmonary artery (PA) remodeling in pulmonary arterial hypertension and other types of pulmonary hypertension.
Read More
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
EMBARK Data Show Continued Improvements With DMD Gene Therapy
March 19th 2025Data from the EMBARK trial of delandistrogene moxeparvovec in patients with Duchenne muscular dystrophy (DMD) show that benefits in functional outcomes, gene expression, and muscle imaging persist 2 years after receiving the gene therapy.
Read More
